Format

Send to

Choose Destination
Endoscopy. 2014 Sep;46(9):799-815. doi: 10.1055/s-0034-1377875. Epub 2014 Aug 22.

Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.

Author information

1
Gedyt Endoscopy Center, Buenos Aires, Argentina.
2
Division of Gastroenterology, Casa Sollievo Sofferemza Hospital, IRCCS, San Giovanni Rotondo, Italy.
3
Division of Gastroenterology, Medical University of South Carolina, Charleston, South Carolina, USA.
4
Division of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Milan, Italy.
5
Department of Gastroenterology, HELIOS Albert-Schweitzer Klinik, Göttingen University Teaching Hospital, Northeim, Germany.
6
Departments of Gastroenterology and Hepato-Pancreatology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
7
Department of Gastroenterology, Silesian Academy of Medicine, Medyków, Katowice, Poland.
8
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
9
Digestive Endoscopy Unit, Catholic University, Rome, Italy.
10
Department of Gastroenterology and Hepatology, Elisabethinen Hospital, Linz, Austria.

Abstract

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recommends routine rectal administration of 100 mg of diclofenac or indomethacin immediately before or after ERCP in all patients without contraindication. In addition to this, in the case of high risk for post-ERCP pancreatitis (PEP), the placement of a 5-Fr prophylactic pancreatic stent should be strongly considered. Sublingually administered glyceryl trinitrate or 250 µg somatostatin given in bolus injection might be considered as an option in high risk cases if nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated and if prophylactic pancreatic stenting is not possible or successful. 2 ESGE recommends keeping the number of cannulation attempts as low as possible. 3 ESGE suggests restricting the use of a pancreatic guidewire as a backup technique for biliary cannulation to cases with repeated inadvertent cannulation of the pancreatic duct; if this method is used, deep biliary cannulation should be attempted using a guidewire rather than the contrast-assisted method and a prophylactic pancreatic stent should be placed. 4 ESGE suggests that needle-knife fistulotomy should be the preferred precut technique in patients with a bile duct dilated down to the papilla. Conventional precut and transpancreatic sphincterotomy present similar success and complication rates; if conventional precut is selected and pancreatic cannulation is easily obtained, ESGE suggests attempting to place a small-diameter (3-Fr or 5-Fr) pancreatic stent to guide the cut and leaving the pancreatic stent in place at the end of ERCP for a minimum of 12 - 24 hours. 4 ESGE does not recommend endoscopic papillary balloon dilation as an alternative to sphincterotomy in routine ERCP, but it may be advantageous in selected patients; if this technique is used, the duration of dilation should be longer than 1 minute.

PMID:
25148137
DOI:
10.1055/s-0034-1377875
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center